| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |